Clinical Trial Detail

NCT ID NCT01176474
Title A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

melanoma

Therapies

NY-ESO-1 peptide vaccine

Ipilimumab

Nivolumab

Age Groups: adult

No variant requirements are available.